Mesoblast Ltd (ASX:MSB) Share Price

Company Profile

Business description
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUS
T: +61 396396036
E: [email protected]
https://www.mesoblast.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
108

Recommended

Morningstar analysts see value in several stocks under fire from shorts.

Lewis Jackson | 12 January 2022

Morningstar had forecast big losses for the drugmaker, which has been dropped from the ASX 200.

Emma Rapaport | 15 June 2020

The biotech giant has jumped 22pc a year for the past decade but new players are emerging.

Nicki Bourlioufas | 07 April 2019

Index	Last price	Change	% Change
All Ordinaries	9,260.90	40.40	0.44%
CAC 40	8,312.25	22.25	-0.27%
DAX 40	26,013.07	245.04	-0.93%
Dow JONES (US)	53,185.90	374.09	-0.70%
FTSE 100	10,756.91	67.35	-0.62%
HKSE	25,329.73	237.26	-0.93%
NASDAQ	26,370.89	31.54	-0.12%
Nikkei 225	66,215.34	96.59	-0.15%
NZX 50 Index	13,786.90	130.40	-0.94%
S&P 500	7,686.14	0.00	0.00%
S&P/ASX 200	9,066.70	41.70	0.46%
SSE Composite Index	3,979.89	6.41	-0.16%